W
ALXN

Wealthfront’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealthfront’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$377K Sell
2,714
-293
-10% -$36.8K ﹤0.01% 413
2018
Q2 		$373K Buy
+3,007
New +$351K ﹤0.01% 408
2017
Q4 		– Sell
-2,038
Closed -$286K – 525
2017
Q3 		$286K Buy
+2,038
New +$277K ﹤0.01% 433
2017
Q2 		– Sell
-1,903
Closed -$231K – 479
2017
Q1 		$231K Sell
1,903
-395
-17% -$50.9K ﹤0.01% 394
2016
Q4 		$281K Buy
2,298
+217
+10% +$26.6K 0.01% 303
2016
Q3 		$255K Buy
+2,081
New +$268K 0.01% 313
2016
Q1 		– Sell
-2,335
Closed -$445K – 363
2015
Q4 		$445K Buy
2,335
+521
+29% +$91K 0.02% 158
2015
Q3 		$284K Buy
1,814
+351
+24% +$64K 0.01% 208
2015
Q2 		$264K Sell
1,463
-676
-32% -$117K 0.01% 212
2015
Q1 		$371K Sell
2,139
-4
-0.2% -$724 0.02% 120
2014
Q4 		$397K Buy
2,143
+633
+42% +$117K 0.02% 87
2014
Q3 		$250K Buy
1,510
+257
+21% +$42.2K 0.02% 119
2014
Q2 		$206K Buy
1,253
+862
+220% +$136K 0.02% 104
2014
Q1 		$61K Buy
+391
New +$62.2K 0.01% 218

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wealthfront's ALXN Position: Q3 2018 in Review

Wealthfront reduced its Alexion Pharmaceuticals (ALXN) stake by 9.7% in Q3 2018, selling an estimated $36.8K and leaving 2,714 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #413.

Wealthfront first reported a position in ALXN in Q1 2014 and has held it in 14 quarters since. The position peaked at $445K in Q4 2015. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Wealthfront held 2,714 shares of Alexion Pharmaceuticals worth $377K as of Q3 2018.
  • Wealthfront sold 293 Alexion Pharmaceuticals shares in Q3 2018, an estimated $36.8K.
  • Alexion Pharmaceuticals made up ﹤0.01% of Wealthfront's portfolio in Q3 2018, its #413 holding.
  • Wealthfront first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 14 quarters since.
  • Wealthfront's Alexion Pharmaceuticals position peaked at $445K in Q4 2015.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.